Neuromod Devices Highlights Evidence-Based Discussion on Lenire Tinnitus Therapy

According to a recent LinkedIn post from Neuromod Devices Ltd, company founder and CEO Dr. Ross O’Neill and Chief Scientific Officer Dr. Hubert Lim recently participated in a discussion with Patrick A. Lynch, CEO of the American Tinnitus Association, focused on Lenire as a treatment option for tinnitus. The post indicates that the conversation addresses key questions from patients and providers, referencing Lenire clinical trial data and real‑world evidence from Lenire providers to offer practical, evidence-based guidance.

For investors, the emphasis on clinical data and real-world outcomes suggests Neuromod is working to strengthen the medical and scientific credibility of Lenire in the tinnitus and hearing-care ecosystem. Featuring the American Tinnitus Association’s leadership in this forum may help Neuromod deepen its engagement with patient advocacy networks and specialist clinicians in audiology and ENT, potentially supporting broader provider adoption. If the discussion effectively reassures clinicians about efficacy and use cases, it could translate into higher utilization of Lenire devices and more predictable revenue streams over time. More broadly, the focus on evidence-based communication aligns with the regulatory and reimbursement requirements typically needed to expand market access for novel neuromodulation therapies, which may be important for Neuromod’s long-term growth trajectory in the tinnitus treatment segment.